Despite the increasing use of intravitreal anti-vascular endothelial growth factor (VEGF) agents to treat retinopathy of prematurity (ROP),1, 2, 3, 4 there are relatively few data on infant outcomes from controlled trials5 and no data describing outcomes into school age. This evidence concerns the gene VEGFA and retinopathy of prematurity.